Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

• Status: COMPLETED
• Trial end date: 2025-02-28

Summary

Sacubitril/valsartan is an established medication for heart failure. However, data still lags in its use in heart failure patients with chronic kidney disease. Sacubitril/valsartan is manufacturer-labeled for use in patients with eGFR \< 30 ml/min/1.73 m2 at an initial dose of 24/26mg twice daily. However, to the best of our knowledge, the concept of sacubitril/valsartan or ACEi in patients with chronic kidney disease \& presenting with decompensated heart failure has not yet been explored fully.

• Phase: PHASE2

Details

• Lead Sponsor: National Heart Institute, Egypt
• Collaborator: Cairo University
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Ramipril; sacubitril and valsartan sodium hydrate drug combination